SARS-CoV-2 spike glycoprotein (B.1 strains)

Active ingredient description

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
J07BN02 J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
VIDPREVTYN BETA Solution and emulsion for emulsion for injection European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

DrugBank Drug: DB16427
UNII Identifier: E68GYP6X53
SARS-COV2 501.V2 VARIANT

Medicines

SARS-CoV-2 spike glycoprotein (B.1 strains) is an active ingredient of these brands:

Austria (AT)

  • BIMERVAX as SARS-CoV-2 spike glycoprotein (B.1.351 and B.1.1.7 strains)

Croatia (HR)

  • BIMERVAX as SARS-CoV-2 spike glycoprotein (B.1.351 and B.1.1.7 strains)

Estonia (EE)

  • BIMERVAX as SARS-CoV-2 spike glycoprotein (B.1.351 and B.1.1.7 strains)

Ireland (IE)

  • BIMERVAX as SARS-CoV-2 spike glycoprotein (B.1.351 and B.1.1.7 strains)

Italy (IT)

  • BIMERVAX as SARS-CoV-2 spike glycoprotein (B.1.351 and B.1.1.7 strains)

Lithuania (LT)

Poland (PL)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.